Stage IV/Recurrent Esophageal Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01-23-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Patients Rising, Launched to Fight for Access to Vital Therapies and Services for Patients with Life-Threatening Diseases (08-25-2015)

Patient advocacy veterans Jonathan and Terry Wilcox today announced the launch of a new not-for-profit organization, Patients Rising. This patient advocacy organization will educate, advocate and communicate the importance of access to vital therapies... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (02-12-2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

Esophageal Cancer Survival Improved Using Targeted Therapy Developed in Lung Cancer (12-4-2014)

Targeted therapy commonly used in lung cancer improves survival of esophageal cancer patients according to clinical trial results recently presented at the National Cancer Research Institute (NCRI) Cancer Conference in the UK. The esophagus is a muscular... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (11-13-2014)

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved... Continue Reading

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer (04-3-2013)

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular... Continue Reading

Surgery Improves Survival in Esophageal Cancer (02-21-2013)

Surgery after chemoradiotherapy—which is the standard of care in advanced esophageal cancer—increased overall and disease-free survival compared with chemoradiotherapy alone, according to the results of a study presented at the 2013 Gastrointestinal... Continue Reading

Iressa Improves Progression-Free Survival in Metastatic Esophageal Cancer (10-5-2012)

Treatment with Iressa® (gefitinib) slowed disease progression and improved quality of life in patients with metastatic esophageal cancer, according to the results of a phase III trial presented at the ESMO 2012 Congress of the European Society for Medical... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Some Patients with Advanced Cancer Continue Screening (10-22-2010)

A significant proportion of patients with advanced cancers continue to undergo cancer screening, even though screening is unlikely to benefit these patients. These findings were recently reported in the Journal of the American Medical Association. Cancer... Continue Reading

Next Page »